Bell's mania

Last updated
Bell's mania
Other namesDelirious mania
Dopamine Transporter Meth.jpg
The hypothesized cause of Bell's mania is said to be abnormally elevated levels of extracellular dopamine.
Specialty Behavioral neurology, psychiatry
Symptoms Hyperactivity, hyperthermia, delirium, disruption in psychomotor activities, emotional liability, fear, panic, aggression, violence, sensory dysfunction, death
CausesDysfunction of dopaminergic transporters, anomalous activation of the dorsal anterior cingulate, right inferior frontal cortical regions, excited hyperdopaminergic mechanism
Risk factors Psychostimulant users and abusers, patients with drug withdrawal, undiagnosed/untreated psychiatric patients, people with severe manic episodes, sleep deprived individuals, people with medical history of neurological and physiological conditions
Differential diagnosis Bipolar disorder, acute schizophrenia, catatonia, delirium
TreatmentRapid sedation, intramuscular ketamine injections, electroconvulsive therapy, blood tests, regulation of body temperature.
Medication Benzodiazepines, antipsychotic medication, ketamine injections, dantrolene

Bell's mania, also known as delirious mania, refers to an acute neurobehavioral syndrome. [1] This is usually characterized by an expeditious onset of delirium, mania, psychosis, followed by grandiosity, emotional lability, altered consciousness, hyperthermia, and in extreme cases, death. [1] It is sometimes misdiagnosed as excited delirium (EXD) or catatonia due to the presence of overlapping symptoms. [2] [3] Pathophysiology studies reveal elevated dopamine levels in the neural circuit as the underlying mechanism. [4] [5] Psychostimulant users as well as individuals experiencing severe manic episodes are more prone to the manifestation of this condition. [6] Management solutions such as sedation and ketamine injections have been discussed for medical professionals and individuals with the condition. Bell's mania cases are commonly reported in countries like the United States and Canada and are commonly associated with psychostimulant use and abuse. [4]

Contents

Clinical features

The majority of Bell's mania cases studied are triggered by psychostimulant drug usage or preexisting medical or neurological conditions, which impedes the apprehension of this syndrome. [7]   Hence at present, there is still no scientific consensus on the clinical features of Bell's mania. Researchers are currently working on varying case studies to derive common clinical characteristics. Some frequent signs and symptoms include acute onset of delirium, mania or psychosis. [8] [3] Patients with Bell's mania have fluctuating severity of symptoms over time with altered consciousness and emotional lability. [9] [6] [10] They tend to be excited, agitated, paranoid, delusional and alarmed. [6] [3] [10] They display impulsive, hostile and destructive behavior towards others that can last for hours to days, as well as unexpected physical strength. [1] Catatonic symptoms such as grimacing, echopraxia, negativism, echolalia and stereotypy are often present. [11] Impaired concentration, memory loss, disorientation, insomnia, auditory and visual hallucinations are additional symptoms that follow. [6] [10] There are shifts from having loud and disorganized speech to mutism. [6]   Some typical physiological signs include hyperthermia, tachycardia, hypertension, and hyperventilation. [12]

Diagnosis

This condition is currently not recognized as a diagnosable issue by psychiatric journals such as the Diagnostic and Statistical Manual of Mental Disorders-IV [3] by the American Psychiatric Association or the tenth revision of the International Statistical Classification of Diseases and Related Health Problems by World Health Organization (WHO). [3]

Physical examination

When examined, patients with Bell's mania fail to recall names, recent experiences and are poorly oriented for location, date, and time. [12] Moreover, their blood pressure and respiratory rate are increased. [13] Additionally, mental status examination using questionnaires [13] and three diagnostic tests are taken, including drawing a clock-face, [14] The Face-Hand test [15] and Hidden figures tests. [16] Patients with Bell's mania tend to make obvious mistakes in these tests, for instance drawing a clock-face with incorrect numbering or missing clock hands. [14]

Differential diagnosis

Upon acute onset of the symptoms, an instant investigation for a toxic or systemic cause is undertaken. [12] Prominence of thought disorder, grandiosity and delusional ideation, and catatonic signs indicates the diagnosis of acute schizophrenia, bipolar disorder and catatonia respectively. [12] Diagnostic complications arise as these signs are also often the notable feature of Bell's mania. [8] With the cause undetermined, Bell's mania diagnosis is usually justified with the presence of both mania and delirium regardless of the catatonic symptoms. [12]

Distinguishing between Bell's mania and catatonia

Bell's mania and catatonia are regarded as "overlapping syndromes", [16] making differential diagnosis essential when catatonic signs are observed. [12] Thus, researchers must distinguish between excited catatonia and Bell's mania, and among malignant catatonia, excited catatonia, and neuroleptic malignant syndrome (NMS). [12] When catatonic features are prominent, it is diagnosed as excited catatonia and when absent or subtle, it is identified as Bell's mania. [12] Alternatively, the presence of delirium is recognized as the discerning factor. A difference between the two is that catatonia is viewed from a movement aspect, whereas delirium from consciousness. [7]

Nevertheless, a formal set of diagnostic criteria is required to distinguish between Bell's mania and catatonia. [11] Failure to diagnose Bell's mania appearing as catatonia could lead to deleterious consequences and, in worse cases, death. [1] [8]

Pathophysiology

Dopamine is the primary neurotransmitter involved in the pathophysiology of Bell's mania. [3] Elevated dopamine levels in the neural circuit concerned with neuropsychiatric disorders are postulated to be responsible for the manic and psychosis symptoms and other signs, including fluctuations in body temperatures and fear. [17] Increased extracellular dopamine levels can be caused by low levels of dopaminergic transporters, sensitization of postsynaptic dopaminergic receptors, and dopamine transporters dysfunction. [6]

Sagittal cross-section of the brain illustrating the dopaminergic pathway. Dopamine Pathways cs.png
Sagittal cross-section of the brain illustrating the dopaminergic pathway.

Role of genetics and signaling pathways

Mania is a prominent symptom of both bipolar disorder and Bell's mania. Hence, studying bipolar patients can provide insight into the pathophysiology of this Bell's mania. PET scans of manic patients illustrate anomalous activation of the dorsal anterior cingulate, right inferior frontal cortical regions. [6] Manic symptoms exacerbate with increasing anterior cingulate activation, which is posited to be associated with escalating dopamine transmission in the nucleus accumbens. [3]

Dopamine transporter regulates the reuptake of dopamine to keep the synaptic dopamine levels within normal range. [6] Hence, the elevation of such transporter levels in the striatum decreases neurotransmission. [18] Genetic studies have hypothesized a relationship between low transporter protein levels and the gene for dopamine transporter in bipolar affective patients. [6]

Stimulant elicited responses

Sensitization of postsynaptic dopaminergic receptors

External sources contributing to the hypothesized hyperdopaminergic mechanism include psychostimulants like cocaine. [6] These substances provoke behavioral changes similar to mania. [19] In chronic users, drug sensitization occurs which induces increased neurotransmission and modified protein expression within the mesolimbic dopamine neurons. Adaptations in dopamine transporters is further triggered causing behavioral sensitization. [20] This phenomenon is not distinct to drug abuse but also other psychomotor stimulants such as stress. [6]

Dopaminergic transporters dysfunction

Dopaminergic transporters dysfunction is caused by acute mania of bipolar disorder, psychostimulant use, and environmental stress. It is suggested to be common mechanism in excited delirium (EXD). [6]  EXD is commonly observed in psychostimulant abusers as these drugs directly impact the dopaminergic transporters, increasing the extracellular dopamine levels. [21] [6]

Amplified excitation of the dopaminergic systems can induce extreme fear and magnify both approach and avoidance behaviors. [6] The hyperdopaminergic state triggers aggression, agitation and psychomotor excitement. [6] Additionally, CNS dopamine signaling is active in heart rate, respiration and body temperature regulation. [22] Dopamine imbalance can hence result in hyperthermia, tachycardia, hyperventilation, hypertension and sleep disturbance symptoms. [6] [3]

Risk Factors

Given that hyperdopaminergic state is postulated to be the underlying mechanism of Bell's Mania, people prone to dopamine imbalance, sensitization and low levels of dopamine transporters are susceptible. [6]   Furthermore, this syndrome is usually precipitated from prevailing neurological and physiological conditions. [12] Hence, those at risk include

Treatment and Management

Whilst the scope of Bell's Mania is extensively studied, there remain some significant challenges that need to be solved with respect to treatment and management. [3]

Recognition

Over the course of time the significance of this syndrome has been increasingly recognized in correspondence to the manner of death, specifically because the anatomic cause of death is hard to define during autopsy. Recent studies have elicited neurochemical imbalances [24] resulting in autonomic hyperactivity and increase in dopamine levels in the victims. [3] Emergency personnel need to recognize these symptoms promptly to avoid the individual from spiraling into metabolic acidosis, rhabdomyolysis, multiorgan failure and ultimately death. In light of the clinical findings, some treatments have been described which include effective sedation, followed closely by external cooling, monitoring medical complications and the administration of intravenous (IV) fluids. [3]

Benzodiazepines are a type of tranquilizers used in the treatment of Bell's Mania that take effect by acting on GABA neurotransmitters in the brain. It helps in bringing extreme agitation and catatonia under control. Etizolam.jpg
Benzodiazepines are a type of tranquilizers used in the treatment of Bell's Mania that take effect by acting on GABA neurotransmitters in the brain. It helps in bringing extreme agitation and catatonia under control.

Rapid Sedation

One management technique is rapid sedation in view of the unpredictable aggressive nature of the patient with Bell's Mania, especially if the symptoms that need to be handled are associated with the causes like dopamine regulation. Turning off the catecholamine cascade and rapidly sedating the patient using several sedatives like Benzodiazepines or Neuroleptics [25] can help. Several studies also point at the increased effectiveness of combination of two or more sedatives in the treatment of hyper agitated patients. [26] [27]

The use of Intramuscular Ketamine Injections is a popular method in the treatment of Bell's Mania. Ketmine Injection.jpg
The use of Intramuscular Ketamine Injections is a popular method in the treatment of Bell's Mania.

Intramuscular Ketamine Injections

Patients with Bell's mania may not have optimum time for the sedatives to start showing effect. Due to this fact, electroconvulsive therapy [1] and Intramuscular Ketamine injections [3] are alternative solutions that have been proposed. With an onset time of 30 seconds to 4 minutes ketamine proves to be more effective than Benzodiazepines. [28] Although adult data on the use of Ketamine on patients isn't readily available, a study by Strayer et al. [29] concluded that the use of ketamine for controlling the hyperactivity was reliable and can further facilitate other management techniques with fewer side effects. [30]

Other Preventative Measures

Along with sedation techniques, a few other prevention and protection measures can decrease fatal outcomes, some of which are:

The urgency and medical severity of the condition needs to be given impetus in terms of handling patients with Bell's Mania. Due to the homologous nature of this syndrome with malignant hyperthermia (MH) and neuroleptic malignant syndrome (NMS), [31] Dantrolene [32] is also a probable treatment route owing to its swift acidosis correction. Although more research is needed in correspondence to the cause and consequences of this disease, the significance of the behavioral and physical symptoms need to be given importance to provide medical institutions as well the constabulary the necessary information to respond to Bell's Mania appropriately.

Epidemiology

The first case of Bell's Mania was observed by medical examiners during the cocaine epidemic [33] [6] in countries like the United States of America and Canada with some other cases being related to police brutality and restraint. [34] The term Bell's Mania was first coined to describe the clinical condition with a 75% mortality rate. [6] The prevalence of this condition ranges from 15% to 25% in the society and, is not an infrequent occurrence. [11]

History

Luther Vose Bell (1806-1862) was the first person to coin the term Bell's Mania. Luther V. Bell.jpg
Luther Vose Bell (1806-1862) was the first person to coin the term Bell's Mania.

First mention of Bell's Mania

Bell's Mania is a syndrome with unexplained etiology which was first explained by American psychiatrist Luther Bell in the 1850s after observing institutionalized psychiatric patients. The first clinical reports and descriptions of people with acute exhaustive mania and delirium were provided by a few psychiatrists in the United States of America, France and the United Kingdom. [6] The description of the symptoms seemed to be quite similar to that of patients with schizophrenia (hallucinations and delirium) however additional hyperactivity, heightened arousal, and altered sleep cycle was also reported in patients with Bell's Mania. [6]

The suggestive symptoms of this disorder were first observed in the 19th century, out of which some of the most significant ones are the onset of aggression, bizarre behavior, violence, excessive shouting, panic, paranoia and increase in body temperature. [4] In 1934, Stauder described a series of acute onset of psychomotor agitation in young people with no history of physical or psychological disturbances. [35] He termed this description as Lethal Catatonia. Other reasons for the manifestation of Bell's Mania, points at the use of stimulant drugs in excessive amounts and also psychiatric diseases like depression or schizophrenia. [12] [36]

In 1985, Bell's Mania was first mentioned in a definitive manner using the term Excited Delirium (EXD). Prior to that year, most cases of death by cocaine intoxication [37] during the cocaine epidemic that happened in a sudden manner. This involved the exposure to highly toxic amounts of the drug due to the bursting of cocaine packets being carried within the body by "body stuffers". [38] In the same year a series of observations were made by Welti and Fishbain regarding psychosis, cardiorespiratory arrest and sudden death [39] in individuals with cocaine addiction. Since the law enforcement were often called to contain violent behavior exhibited by these individuals. It was speculated that police brutality might be the underlying cause of the misshapen. Upon medical review of the cases related to the use of batons, pepper sprays and restraint methods [38] did not disclose any autonomic cause behind the death, albeit problems like cardiac diseases and trauma was excluded from the extensive evaluation. [38] [4] [5]

See also

Related Research Articles

<span class="mw-page-title-main">Catatonia</span> Psychiatric behavioral syndrome

Catatonia is a complex neuropsychiatric behavioral syndrome that is characterized by abnormal movements, immobility, abnormal behaviors, and withdrawal. The onset of catatonia can be acute or subtle and symptoms can wax, wane, or change during episodes. It has historically been related to schizophrenia, but catatonia is most often seen in mood disorders. It is now known that catatonic symptoms are nonspecific and may be observed in other mental, neurological, and medical conditions. Catatonia is not a stand-alone diagnosis, and the term is used to describe a feature of the underlying disorder.

Mania, also known as manic syndrome, is a mental and behavioral disorder defined as a state of abnormally elevated arousal, affect, and energy level, or "a state of heightened overall activation with enhanced affective expression together with lability of affect." During a manic episode, an individual will experience rapidly changing emotions and moods, highly influenced by surrounding stimuli. Although mania is often conceived as a "mirror image" to depression, the heightened mood can be either euphoric or dysphoric. As the mania intensifies, irritability can be more pronounced and result in anxiety or anger.

<span class="mw-page-title-main">Mood stabilizer</span> Psychiatric medication used to treat mood disorders

A mood stabilizer is a psychiatric medication used to treat mood disorders characterized by intense and sustained mood shifts, such as bipolar disorder and the bipolar type of schizoaffective disorder.

Psychosis is a condition of the mind that results in difficulties determining what is real and what is not real. Symptoms may include delusions and hallucinations, among other features. Additional symptoms are incoherent speech and behavior that is inappropriate for a given situation. There may also be sleep problems, social withdrawal, lack of motivation, and difficulties carrying out daily activities. Psychosis can have serious adverse outcomes.

<span class="mw-page-title-main">Psychopharmacology</span> Study of the effects of psychoactive drugs

Psychopharmacology is the scientific study of the effects drugs have on mood, sensation, thinking, behavior, judgment and evaluation, and memory. It is distinguished from neuropsychopharmacology, which emphasizes the correlation between drug-induced changes in the functioning of cells in the nervous system and changes in consciousness and behavior.

<span class="mw-page-title-main">Chlorpromazine</span> Antipsychotic medication

Chlorpromazine (CPZ), marketed under the brand names Thorazine and Largactil among others, is an antipsychotic medication. It is primarily used to treat psychotic disorders such as schizophrenia. Other uses include the treatment of bipolar disorder, severe behavioral problems in children including those with attention deficit hyperactivity disorder, nausea and vomiting, anxiety before surgery, and hiccups that do not improve following other measures. It can be given orally, by intramuscular injection, or intravenously.

<span class="mw-page-title-main">Haloperidol</span> Typical antipsychotic medication

Haloperidol, sold under the brand name Haldol among others, is a typical antipsychotic medication. Haloperidol is used in the treatment of schizophrenia, tics in Tourette syndrome, mania in bipolar disorder, delirium, agitation, acute psychosis, and hallucinations from alcohol withdrawal. It may be used by mouth or injection into a muscle or a vein. Haloperidol typically works within 30 to 60 minutes. A long-acting formulation may be used as an injection every four weeks by people with schizophrenia or related illnesses, who either forget or refuse to take the medication by mouth.

<span class="mw-page-title-main">Olanzapine</span> Atypical antipsychotic medication

Olanzapine is an atypical antipsychotic primarily used to treat schizophrenia and bipolar disorder. For schizophrenia, it can be used for both new-onset disease and long-term maintenance. It is taken by mouth or by injection into a muscle.

<span class="mw-page-title-main">Aripiprazole</span> Atypical antipsychotic

Aripiprazole, sold under the brand names Abilify and Aristada, among others, is an atypical antipsychotic. It is primarily used in the treatment of schizophrenia, obsessive compulsive disorder (OCD), and bipolar disorder; other uses include as an add-on treatment in major depressive disorder, tic disorders, and irritability associated with autism. Aripiprazole is taken by mouth or via injection into a muscle. A Cochrane review found low-quality evidence of effectiveness in treating schizophrenia.

Stimulant psychosis is a mental disorder characterized by psychotic symptoms. It involves and typically occurs following an overdose or several day 'binge' on psychostimulants; however, one study reported occurrences at regularly prescribed doses in approximately 0.1% of individuals within the first several weeks after starting amphetamine or methylphenidate therapy. Methamphetamine psychosis, or long-term effects of stimulant use in the brain, depend upon genetics and may persist for some time.

A dopamine reuptake inhibitor (DRI) is a class of drug which acts as a reuptake inhibitor of the monoamine neurotransmitter dopamine by blocking the action of the dopamine transporter (DAT). Reuptake inhibition is achieved when extracellular dopamine not absorbed by the postsynaptic neuron is blocked from re-entering the presynaptic neuron. This results in increased extracellular concentrations of dopamine and increase in dopaminergic neurotransmission.

Psychomotor agitation is a symptom in various disorders and health conditions. It is characterized by unintentional and purposeless motions and restlessness, often but not always accompanied by emotional distress. Typical manifestations include pacing around, wringing of the hands, uncontrolled tongue movement, pulling off clothing and putting it back on, and other similar actions. In more severe cases, the motions may become harmful to the individual, and may involve things such as ripping, tearing, or chewing at the skin around one's fingernails, lips, or other body parts to the point of bleeding. Psychomotor agitation is typically found in various mental disorders, especially in psychotic and mood disorders. It can be a result of drug intoxication or withdrawal. It can also be caused by severe hyponatremia. The middle-aged and the elderly are more at risk to express it.

α-Methyl-<i>p</i>-tyrosine Chemical compound

α-Methyl-p-tyrosine (AMPT), or simply α-methyltyrosine, also known in its chiral 2-(S) form as metirosine, is a tyrosine hydroxylase enzyme inhibitor and is therefore a drug involved in inhibiting the catecholamine biosynthetic pathway. AMPT inhibits tyrosine hydroxylase whose enzymatic activity is normally regulated through the phosphorylation of different serine residues in regulatory domain sites. Catecholamine biosynthesis starts with dietary tyrosine, which is hydroxylated by tyrosine hydroxylase and it is hypothesized that AMPT competes with tyrosine at the tyrosine-binding site, causing inhibition of tyrosine hydroxylase.

<span class="mw-page-title-main">Dopaminergic</span> Substance related to dopamine functions

Dopaminergic means "related to dopamine" (literally, "working on dopamine"), dopamine being a common neurotransmitter. Dopaminergic substances or actions increase dopamine-related activity in the brain. Dopaminergic brain pathways facilitate dopamine-related activity. For example, certain proteins such as the dopamine transporter (DAT), vesicular monoamine transporter 2 (VMAT2), and dopamine receptors can be classified as dopaminergic, and neurons that synthesize or contain dopamine and synapses with dopamine receptors in them may also be labeled as dopaminergic. Enzymes that regulate the biosynthesis or metabolism of dopamine such as aromatic L-amino acid decarboxylase or DOPA decarboxylase, monoamine oxidase (MAO), and catechol O-methyl transferase (COMT) may be referred to as dopaminergic as well. Also, any endogenous or exogenous chemical substance that acts to affect dopamine receptors or dopamine release through indirect actions (for example, on neurons that synapse onto neurons that release dopamine or express dopamine receptors) can also be said to have dopaminergic effects, two prominent examples being opioids, which enhance dopamine release indirectly in the reward pathways, and some substituted amphetamines, which enhance dopamine release directly by binding to and inhibiting VMAT2.

<span class="mw-page-title-main">Asenapine</span> Medication to treat schizophrenia

Asenapine, sold under the brand name Saphris among others, is an atypical antipsychotic medication used to treat schizophrenia and acute mania associated with bipolar disorder as well as the medium to long-term management of bipolar disorder.

Oneiroid syndrome (OS) is a condition involving dream-like disturbances of one's consciousness by vivid scenic hallucinations, accompanied by catatonic symptoms (either catatonic stupor or excitement), delusions, or psychopathological experiences of a kaleidoscopic nature. The term is from Ancient Greek "ὄνειρος" (óneiros, meaning "dream") and "εἶδος" (eîdos, meaning "form, likeness"; literally dream-like / oneiric or oniric, sometimes called "nightmare-like"). It is a common complication of catatonic schizophrenia, although it can also be caused by other mental disorders. The dream-like experiences are vivid enough to seem real to the patient. OS is distinguished from delirium by the fact that the imaginative experiences of patients always have an internal projection. This syndrome is hardly mentioned in standard psychiatric textbooks, possibly because it is not listed in DSM.

Excited delirium (ExDS), also known as agitated delirium (AgDS) or hyperactive delirium syndrome with severe agitation, is a controversial and widely rejected diagnosis characterized as a potentially fatal state of extreme agitation and delirium. It has typically been diagnosed postmortem in young adult black males who were physically restrained by law enforcement personnel at the time of death.

<span class="mw-page-title-main">Postpartum psychosis</span> Rare psychiatric emergency beginning suddenly in the first two weeks after childbirth

Postpartum psychosis(PPP), also known as puerperal psychosis or peripartum psychosis, involves the abrupt onset of psychotic symptoms shortly following childbirth, typically within two weeks of delivery but less than 4 weeks postpartum. PPP is a condition currently represented under "Brief Psychotic Disorder" in the Diagnostic and Statistical Manual of Mental Disorders, Volume V (DSM-V). Symptoms may include delusions, hallucinations, disorganized speech (e.g, incoherent speech), and/or abnormal motor behavior (e.g., catatonia). Other symptoms frequently associated with PPP include confusion, disorganized thought, severe difficulty sleeping, variations of mood disorders (including depression, agitation, mania, or a combination of the above), as well as cognitive features such as consciousness that comes and goes (waxing and waning) or disorientation.

<span class="mw-page-title-main">Amphetamine dependence</span> Medical condition

Amphetamine dependence refers to a state of psychological dependence on a drug in the amphetamine class. Stimulants such as amphetamines and cocaine do not cause somatic symptoms upon cessation of use but rather neurological-based mental symptoms.

References

  1. 1 2 3 4 5 Bobo, William V.; Murphy, Michael J.; Heckers, Stephan H. (May 2009). "Recurring episodes of Bell's mania after cerebrovascular accident". Psychosomatics. 50 (3): 285–288. doi: 10.1176/appi.psy.50.3.285 . ISSN   1545-7206. PMID   19567770.
  2. ↑ Emergency Medical Service. ALUNA. doi:10.36740/emems. S2CID   7546377.
  3. 1 2 3 4 5 6 7 8 9 10 11 12 13 Takeuchi, Asia; Ahern, Terence L.; Henderson, Sean O. (February 2011). "Excited Delirium". Western Journal of Emergency Medicine. 12 (1): 77–83. ISSN   1936-900X. PMC   3088378 . PMID   21691475.
  4. 1 2 3 4 Wetli, Charles V.; Fishbain, David A. (1985-07-01). "Cocaine-Induced Psychosis and Sudden Death in Recreational Cocaine Users". Journal of Forensic Sciences. 30 (3): 873–880. doi:10.1520/jfs11020j. ISSN   0022-1198. PMID   4031813.
  5. 1 2 Ruttenber, A. James; Lawler-Heavner, Janet; Yin, Ming; Wetli, Charles V.; Hearn, W. Lee; Mash, Deborah C. (1997-01-01). "Fatal Excited Delirium Following Cocaine Use: Epidemiologic Findings Provide New Evidence for Mechanisms of Cocaine Toxicity". Journal of Forensic Sciences. 42 (1): 25–31. doi:10.1520/jfs14064j. ISSN   0022-1198. PMID   8988571.
  6. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 Mash, Deborah C. (2016). "Excited Delirium and Sudden Death: A Syndromal Disorder at the Extreme End of the Neuropsychiatric Continuum". Frontiers in Physiology. 7: 435. doi: 10.3389/fphys.2016.00435 . ISSN   1664-042X. PMC   5061757 . PMID   27790150.
  7. 1 2 Lee, Bo-Shyan; Huang, Si-Sheng; Hsu, Wen-Yu; Chiu, Nan-Ying (2012-06-21). "Clinical features of delirious mania: a series of five cases and a brief literature review". BMC Psychiatry. 12: 65. doi:10.1186/1471-244X-12-65. ISSN   1471-244X. PMC   3503657 . PMID   22716018.
  8. 1 2 3 JACOBOWSKI, NATALIE L.; HECKERS, STEPHAN; BOBO, WILLIAM V. (January 2013). "Delirious Mania". Journal of Psychiatric Practice. 19 (1): 15–28. doi:10.1097/01.pra.0000426324.67322.06. ISSN   1538-1145. PMID   23334676. S2CID   10286031.
  9. ↑ Wetli, C.V. (2005), "Excited Delirium", Encyclopedia of Forensic and Legal Medicine, Elsevier, pp. 276–281, doi:10.1016/b0-12-369399-3/00311-6, ISBN   978-0-12-369399-0 , retrieved 2021-04-01
  10. 1 2 3 Karmacharya, Rakesh; England, Mary Lou; Öngür, Dost (2008-08-01). "Delirious mania: Clinical features and treatment response". Journal of Affective Disorders. 109 (3): 312–316. doi:10.1016/j.jad.2007.12.001. ISSN   0165-0327. PMID   18191210.
  11. 1 2 3 4 Cordeiro, Catarina R.; Saraiva, Rodrigo; Côrte-Real, Beatriz; Pestana, Pedro Câmara; Andrade, Gabriela; Fernandes, Elsa; Castanheira, LÃ-gia; Martins, and Paulo (2020-04-09). "When the Bell Rings". The Primary Care Companion for CNS Disorders. 22 (2). doi:10.4088/PCC.19l02511. PMID   32286746. S2CID   215758935.
  12. 1 2 3 4 5 6 7 8 9 10 11 12 Fink, Max (1999). "Delirious mania". Bipolar Disorders. 1 (1): 54–60. doi:10.1034/j.1399-5618.1999.10112.x. ISSN   1399-5618. PMID   11256658.
  13. 1 2 Bipeta, Rajshekhar; Khan, Majeed A. (2012-11-12). "Delirious Mania: Can We Get Away with This Concept? A Case Report and Review of the Literature". Case Reports in Psychiatry. 2012: 720354. doi: 10.1155/2012/720354 . PMC   3502817 . PMID   23198239.
  14. 1 2 "The Clock Drawing Test", Quick Cognitive Screening for Clinicians, Abingdon, UK: Taylor & Francis, 2003, doi:10.4324/9780203427170_chapter_4, ISBN   978-0-203-44696-6 , retrieved 2021-04-01
  15. ↑ Patten, S. B.; Lamarre, C. J. (November 1989). "The face-hand test: a useful addition to the psychiatric physical examination". Psychiatric Journal of the University of Ottawa. 14 (4): 554–556. ISSN   0702-8466. PMID   2813636.
  16. 1 2 KAHN, ROBERT L.; POLLACK, MAX; FINK, MAX (1960-05-01). "Figure-Ground Discrimination After Induced Altered Brain Function". Archives of Neurology. 2 (5): 547–551. doi:10.1001/archneur.1960.03840110061007. ISSN   0375-8540. PMID   14404003.
  17. ↑ Cipriani, Andrea; Barbui, Corrado; Salanti, Georgia; Rendell, Jennifer; Brown, Rachel; Stockton, Sarah; Purgato, Marianna; Spineli, Loukia M; Goodwin, Guy M; Geddes, John R (October 2011). "Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis". The Lancet. 378 (9799): 1306–1315. doi:10.1016/S0140-6736(11)60873-8. PMID   21851976. S2CID   25512763.
  18. ↑ Ashok, A. H.; Marques, T. R.; Jauhar, S.; Nour, M. M.; Goodwin, G. M.; Young, A. H.; Howes, O. D. (May 2017). "The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment". Molecular Psychiatry. 22 (5): 666–679. doi:10.1038/mp.2017.16. ISSN   1476-5578. PMC   5401767 . PMID   28289283.
  19. ↑ Silverstone, Trevor; Wells, Brian; Trenchard, Esther (February 1983). "Differential dose-response effects of dexamphetamine sulphate on hunger, arousal and mood in human volunteers". Psychopharmacology. 79 (2–3): 242–245. doi:10.1007/BF00427820. ISSN   0033-3158. PMID   6405435. S2CID   22272809.
  20. ↑ Kalivas, PW; Duffy, P (1993-01-01). "Time course of extracellular dopamine and behavioral sensitization to cocaine. I. Dopamine axon terminals". The Journal of Neuroscience. 13 (1): 266–275. doi:10.1523/jneurosci.13-01-00266.1993. ISSN   0270-6474. PMC   6576317 . PMID   8423473.
  21. ↑ Penders, Thomas M.; Gestring, Richard E.; Vilensky, Dmitry A. (November 2012). "Intoxication Delirium following Use of Synthetic Cathinone Derivatives". The American Journal of Drug and Alcohol Abuse. 38 (6): 616–617. doi:10.3109/00952990.2012.694535. ISSN   0095-2990. PMID   22783894. S2CID   207428569.
  22. ↑ Mann, S. C.; Boger, W. P. (September 1978). "Psychotropic drugs, summer heat and humidity, and hyperpyrexia: a danger restated". American Journal of Psychiatry. 135 (9): 1097–1100. doi:10.1176/ajp.135.9.1097. ISSN   0002-953X. PMID   29501.
  23. ↑ Vilke, Gary M.; DeBard, Mark L.; Chan, Theodore C.; Ho, Jeffrey D.; Dawes, Donald M.; Hall, Christine; Curtis, Michael D.; Costello, Melissa Wysong; Mash, Deborah C.; Coffman, Stewart R.; McMullen, Mary Jo (November 2012). "Excited Delirium Syndrome (ExDS): Defining Based on a Review of the Literature". The Journal of Emergency Medicine. 43 (5): 897–905. doi:10.1016/j.jemermed.2011.02.017. PMID   21440403.
  24. ↑ Richter, Diethelm W.; Mironov, Sergej L.; Büsselberg, Dietrich; Lalley, Peter M.; Bischoff, Anne M.; Wilken, Bernd (June 2000). "Respiratory Rhythm Generation: Plasticity of a Neuronal Network". The Neuroscientist. 6 (3): 181–198. doi:10.1177/107385840000600309. ISSN   1073-8584. S2CID   85237863.
  25. ↑ Seitz, Dallas P.; Gill, Sudeep S.; van Zyl, Louis T. (2007-01-15). "Antipsychotics in the Treatment of Delirium". The Journal of Clinical Psychiatry. 68 (1): 11–21. doi:10.4088/jcp.v68n0102. ISSN   0160-6689. PMID   17284125.
  26. ↑ Bieniek, Sherrie A.; Ownby, Raymond L.; Penalver, Alberto; Dominguez, Roberto A. (1998-01-02). "A Double-Blind Study of Lorazepam versus the Combination of Haloperidol and Lorazepam in Managing Agitation". Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 18 (1): 57–62. doi:10.1002/j.1875-9114.1998.tb03827.x. ISSN   0277-0008. PMID   9469682. S2CID   24505811.
  27. ↑ Battaglia, John; Moss, Sue; Rush, John; Kang, Jasbir; Mendoza, Ricardo; Leedom, Liane; Dubin, William; McGlynn, Charles; Goodman, Lowell (July 1997). "Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study". The American Journal of Emergency Medicine. 15 (4): 335–340. doi:10.1016/s0735-6757(97)90119-4. ISSN   0735-6757. PMID   9217519.
  28. ↑ Green, Steven M; Rothrock, Steven G; Lynch, Elizabeth L; Ho, Matthew; Harris, Troy; Hestdalen, Rodney; Hopkins, G.Alan; Garrett, Wayne; Westcott, Kelli (June 1998). "Intramuscular Ketamine for Pediatric Sedation in the Emergency Department: Safety Profile in 1,022 Cases". Annals of Emergency Medicine. 31 (6): 688–697. doi:10.1016/s0196-0644(98)70226-4. ISSN   0196-0644. PMID   9624307.
  29. ↑ Strayer, Reuben J.; Nelson, Lewis S. (November 2008). "Adverse events associated with ketamine for procedural sedation in adults". The American Journal of Emergency Medicine. 26 (9): 985–1028. doi:10.1016/j.ajem.2007.12.005. ISSN   0735-6757. PMID   19091264.
  30. ↑ Melamed, Eitan; Oron, Yahav; Ben-Avraham, Ron; Blumenfeld, Amir; Lin, Guy (October 2007). "The combative multitrauma patient: a protocol for prehospital management". European Journal of Emergency Medicine. 14 (5): 265–268. doi:10.1097/mej.0b013e32823a3c9b. ISSN   0969-9546. PMID   17823561. S2CID   1197543.
  31. ↑ "Neuroleptic Malignant Syndrome: A Rare, Dangerous Effect of Antipsychotic Drugs". WebMD. Retrieved 2021-04-10.
  32. ↑ Allam, S.; Noble, J. S. (April 2001). "Cocaine-excited delirium and severe acidosis". Anaesthesia. 56 (4): 385–386. doi:10.1046/j.1365-2044.2001.01976-24.x. ISSN   0003-2409. PMID   11284850. S2CID   35080299.
  33. ↑ "The Crack Epidemic - The History of Crack Cocaine - Drug-Free World". Foundation for a Drug-Free World. Retrieved 2021-05-24.
  34. ↑ Stratton, Samuel J.; Rogers, Christopher; Brickett, Karen; Gruzinski, Ginger (May 2001). "Factors associated with sudden death of individuals requiring restraint for excited delirium". The American Journal of Emergency Medicine. 19 (3): 187–191. doi:10.1053/ajem.2001.22665. ISSN   0735-6757. PMID   11326341.
  35. ↑ Stauder, K. H. (December 1934). "Die tödliche Katatonie". Archiv für Psychiatrie und Nervenkrankheiten. 102 (1): 614–634. doi:10.1007/bf01813829. ISSN   0003-9373. S2CID   38213417.
  36. ↑ Pollanen, Michael S; Smith, Charles R; Chiasson, David A; Cairns, James T; Young, James (April 2002). "Fatal child abuse-maltreatment syndrome". Forensic Science International. 126 (2): 101–104. doi:10.1016/s0379-0738(02)00008-7. ISSN   0379-0738. PMID   12084484.
  37. ↑ Fishbain, David A.; Wetli, Charles V. (October 1981). "Cocaine intoxication, delirium, and death in a body packer". Annals of Emergency Medicine. 10 (10): 531–532. doi:10.1016/s0196-0644(81)80010-8. ISSN   0196-0644. PMID   7283219.
  38. 1 2 3 Wetli, Charles V. (March 1987). "Fatal Cocaine Intoxication". The American Journal of Forensic Medicine and Pathology. 8 (1): 1–2. doi:10.1097/00000433-198703000-00001. ISSN   0195-7910. PMID   3578198.
  39. ↑ Wetli, Charles V.; Fishbain, David A. (1985-07-01). "Cocaine-Induced Psychosis and Sudden Death in Recreational Cocaine Users". Journal of Forensic Sciences. 30 (3): 873–880. doi:10.1520/JFS11020J. PMID   4031813.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.